Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Casdozokitug by Coherus BioSciences for Renal Cell Carcinoma: Likelihood of Approval
Casdozokitug is under clinical development by Coherus BioSciences and currently in Phase II for Renal Cell Carcinoma. According to GlobalData,...
Casdozokitug by Coherus BioSciences for Solid Tumor: Likelihood of Approval
Casdozokitug is under clinical development by Coherus BioSciences and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Casdozokitug by Coherus BioSciences for Hepatocellular Carcinoma: Likelihood of Approval
Casdozokitug is under clinical development by Coherus BioSciences and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase...
Casdozokitug by Coherus BioSciences for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
Casdozokitug is under clinical development by Coherus BioSciences and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to...
Casdozokitug by Coherus BioSciences for Non-Small Cell Lung Cancer: Likelihood of Approval
Casdozokitug is under clinical development by Coherus BioSciences and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Casdozokitug by Coherus BioSciences for Squamous Non-Small Cell Lung Carcinoma: Likelihood of Approval
Casdozokitug is under clinical development by Coherus BioSciences and currently in Phase II for Squamous Non-Small Cell Lung Carcinoma. According...
Risk adjusted net present value: What is the current valuation of Coherus BioSciences's Casdozokitug?
Casdozokitug is a monoclonal antibody commercialized by Coherus BioSciences, with a leading Phase II program in Squamous Non-Small Cell Lung...